Insider · CIK 0001568678

Mattes Glenn R.

Reports to the SEC for 2 companies · FLEMINGTON, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001568678

Forms 4 and 5

Insider transactions

39 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-05-16	TFF Pharmaceuticals, Inc.P Purchase	Director, President and CEO	PPurchase	+16K sh	$4.78	+$76.5K	36,000
2021-09-16	TFF Pharmaceuticals, Inc.P Purchase	Director, President and CEO	PPurchase	+10K sh	$7.10	+$71K	20,000
2021-03-15	TFF Pharmaceuticals, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+50K sh	$2.50	+$125K	60,000
2021-03-15	TFF Pharmaceuticals, Inc.S Sale	Director, President and CEO	SSale	−50K sh	$17.04	−$852K	10,000
2021-03-15	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−50K sh	—	—	944,227
2021-02-16	TFF Pharmaceuticals, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+40K sh	$2.50	+$100K	50,000
2021-02-16	TFF Pharmaceuticals, Inc.S Sale	Director, President and CEO	SSale	−40K sh	$16.82	−$673K	10,000
2021-02-16	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−40K sh	—	—	994,227
2021-01-15	TFF Pharmaceuticals, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+40K sh	$2.50	+$100K	50,000
2021-01-15	TFF Pharmaceuticals, Inc.S Sale	Director, President and CEO	SSale	−40K sh	$17.51	−$700K	10,000
2021-01-15	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−40K sh	—	—	1,034,227
2020-12-23	TFF Pharmaceuticals, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+30K sh	$2.50	+$75K	40,000
2020-12-23	TFF Pharmaceuticals, Inc.S Sale	Director, President and CEO	SSale	−30K sh	$15.33	−$460K	10,000
2020-12-23	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−30K sh	—	—	1,074,227
2020-11-10	TFF Pharmaceuticals, Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+109K sh	$2.50	+$272K	118,830
2020-11-10	TFF Pharmaceuticals, Inc.S Sale	Director, President and CEO	SSale	−109K sh	$14.99	−$1.63M	10,000
2020-11-10	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−109K sh	—	—	1,104,227
2020-09-25	TFF Pharmaceuticals, Inc.S Sale	Director, President and CEO	SSale	−3,000 sh	$17.00	−$51K	7,000
2020-08-24	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)A Award	Director, President and CEO	AAward	+152K sh	—	—	1,213,057
2019-11-29	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)A Award	Director, President and CEO	AAward	+90K sh	—	—	1,061,057
2019-11-29	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)A Award	Director, President and CEO	AAward	+25.2K sh	—	—	971,105
2019-10-29	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)A Award	Director, President and CEO	AAward	+333K sh	—	—	945,891
2019-10-29	TFF Pharmaceuticals, Inc.Stock Options (Right to Buy)A Award	Director, President and CEO	AAward	+333K sh	—	—	945,891
2019-10-25	TFF Pharmaceuticals, Inc.P Purchase	Director, President and CEO	PPurchase	+10K sh	$5.00	+$50K	10,000
2019-10-25	TFF Pharmaceuticals, Inc.P Purchase	Director, President and CEO	PPurchase	+10K sh	$5.00	+$50K	10,000
2019-10-25	TFF Pharmaceuticals, Inc.P Purchase	Director, President and CEO	PPurchase	+10K sh	$5.00	+$50K	10,000
2014-01-24	Arno Therapeutics, IncStock Option (right to buy)A Award	Director, President & CEO	AAward	+409K sh	—	—	408,892
2013-11-04	Arno Therapeutics, IncStock Option (right to buy)A Award	Director, President & CEO	AAward	+387K sh	—	—	386,697
2013-10-29	Arno Therapeutics, IncC Conversion	Director, President & CEO	CConversion	+22.2K sh	$2.40	+$53.3K	54,704
2013-10-29	Arno Therapeutics, IncA Award	Director, President & CEO	AAward	+1,666 sh	$2.40	+$3,998.4	56,370
2013-10-29	Arno Therapeutics, IncP Purchase	Director, President & CEO	PPurchase	+20.8K sh	—	—	77,203
2013-10-29	Arno Therapeutics, Inc8% Senior Convertible DebenturesC Conversion	Director, President & CEO	CConversion	−20.8K sh	—	—	0
2013-10-29	Arno Therapeutics, Inc2012 Series B Warrants (right to buy)D Disposition to Issuer	Director, President & CEO	DDisposition to Issuer	−20.8K sh	—	—	0
2013-10-29	Arno Therapeutics, Inc2012 Series B Warrants (right to buy)A Award	Director, President & CEO	AAward	+20.8K sh	—	—	20,833
2013-10-29	Arno Therapeutics, Inc2013 Series D Warrants (right to buy)P Purchase	Director, President & CEO	PPurchase	+20.8K sh	—	—	20,833
2013-10-29	Arno Therapeutics, Inc2013 Series E Warrants (right to buy)P Purchase	Director, President & CEO	PPurchase	+20.8K sh	—	—	20,833
2013-05-28	Arno Therapeutics, IncJ Other	Director, President & CEO	JOther	+3,222 sh	$0.30	+$966.6	259,888
2013-04-29	Arno Therapeutics, IncJ Other	Director, President & CEO	JOther	+3,333 sh	$0.30	+$999.9	256,666
2013-03-27	Arno Therapeutics, IncJ Other	Director, President & CEO	JOther	+3,333 sh	$0.30	+$999.9	253,333

Recent filings

Accepted (ET)
May 174
Mattes Glenn R.0001213900-22-027791
SEC(opens sec.gov)
Sep 164
Mattes Glenn R.0001213900-21-048369
SEC(opens sec.gov)
Mar 174
Mattes Glenn R.0001213900-21-016183
SEC(opens sec.gov)
Feb 184
Mattes Glenn R.0001213900-21-010415
SEC(opens sec.gov)
Jan 204
Mattes Glenn R.0001213900-21-003298
SEC(opens sec.gov)
Dec 294
Mattes Glenn R.0001213900-20-045177
SEC(opens sec.gov)
Nov 134
Mattes Glenn R.0001213900-20-037057
SEC(opens sec.gov)
Aug 264
Mattes Glenn R.0001213900-20-023893
SEC(opens sec.gov)

Companies

Address

200 ROUTE 31 NORTH SUITE 104

FLEMINGTON, NJ, 08822